Location: Solmed Polyclinic (Zagreb)
Study Drug: Experimental drug “transfers” cholesterol from bad particles (LDL) to good particles (HDL) of cholesterol.
Main Inclusion Criteria: Patients who have or have had a blocked blood vessel anywhere in the body and, with existing lipid-lowering therapy, have high cholesterol (LDL) >1.8 mmol/L.
Status: Enrolling patients
Expected Start of Patient Enrollment: May 2023.
Planned completion of new patient enrollment: April 2024
